Search

The Gerstner Sloan Kettering Graduate School of Biomedical Sciences welcomes 21 students to the Summer Undergraduate Research Program.

… Friday, May 26, 2017 The 2017 Summer Undergraduate Research Program (SURP) began with the arrival of 21 undergraduate students, under the auspices of the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK). This year’s SURP class includes 13 women and eight men, all of whom are undergraduates

Neuro-oncologist Dr. Adrienne Boire discusses her path to becoming a cancer researcher, and on the parallel between science and another passion — knitting.

… Friday, January 10, 2025 Adrienne Boire, MD, PhD , has been a knitter almost her entire life. In the famously frigid plains of Minnesota, where Dr. Boire grew up, knitting is taught as part of regular elementary education. It’s a way to make math fun for kids, teach concentration skills, and let them

MSK investigators have shown that a gene mutation linked to many kinds of cancer can also cause birth defects of the nervous system.

… Friday, February 26, 2016 Summary MSK investigators have shown that a mutation in a gene called PTEN that’s linked to many kinds of cancer can also cause birth defects of the nervous system. Their research unveils the mechanism by which the mutation affects cell shape and prevents cells from properly

Breast cancer affects one in eight women in the United States, with approximately 70 to 80 percent of employed breast cancer survivors returning to work three to eighteen months following diagnosis. Job loss can have devastating financial consequences, including increased risk of bankruptcy and debt. Victoria Blinder, MD, medical oncologist at Memorial Sloan Kettering, conducted a longitudinal study of a racially and ethnically diverse sample of employed women undergoing treatment for stage I-III breast cancer in New York City. For more information on this study, published in Health Affairs on February 6, 2017, and to speak with the study author, contact [email protected].

… Tuesday, February 7, 2017 Breast cancer affects one in eight women in the United States, with approximately 70 to 80 percent of employed breast cancer survivors returning to work three to eighteen months following diagnosis.  Job loss can have devastating financial consequences, including increased risk

As flu season ramps up amid the continuing uncertainty of the COVID-19 pandemic, MSK held an Information Session for Patients and Caregivers with the goal of helping people understand the risks and what precautions they could take to safeguard against the flu.

… Monday, November 16, 2020 As flu season ramps up amid the continuing uncertainty of the COVID-19 pandemic, MSK held an Information Session for Patients and Caregivers with the goal of helping people understand the risks and what precautions they could take to safeguard against the flu this year. The

Investigators have sequenced the genome of adenoid cystic carcinoma, a rare and deadly head and neck cancer. The work sets the stage for the sequencing of additional rare cancers at Memorial Sloan Kettering.

… Friday, May 24, 2013 Summary Investigators have sequenced the genome of adenoid cystic carcinoma, a rare and deadly head and neck cancer. The work sets the stage for the sequencing of additional rare cancers at Memorial Sloan Kettering. Since the completion of the Human Genome Project in 2003, many researchers

Sloan Kettering Institute scientists report new findings about a gene that helps regulate DNA methylation.

… Friday, April 9, 2021 The DNA in our genes contains the instructions needed to manufacture all of the proteins in our cells. These proteins, in turn, do the work that keeps our bodies functioning. Therefore, knowing how individual proteins get made can help us understand the causes of human disease,

Learn about how The Society of Memorial Sloan Kettering is supporting precision medicine at MSK Kids.

… Wednesday, April 1, 2020 On February 5, The Society of Memorial Sloan Kettering hosted its seventh annual Winter Lunch to support its Precision Medicine for MSK Kids initiative. More than 275 guests attended this year’s event, which was sponsored by Net-a-Porter for the fifth consecutive year, at the

Mutations in a gene called FOXA1 are responsible for a distinct class of prostate cancer tumors, MSK researchers have found.

… Wednesday, June 26, 2019 Summary Researchers at Memorial Sloan Kettering have identified molecular changes in a protein that promote a distinct type of prostate cancer. The findings suggest that this protein could be a good drug target for men with this form of the disease. Prostate cancer is not one

Antibody-drug conjugates and checkpoint inhibitors show promise as new therapies for bladder cancer.

… Monday, September 12, 2022 Promising new drugs have begun to transform the treatment of bladder (or urothelial) cancer, the sixth most common form of the disease in the U.S., and the fourth most common in men. In particular, two drug classes, antibody-drug conjugates (ADCs) and checkpoint inhibitors,